Status:
UNKNOWN
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas
Lead Sponsor:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborating Sponsors:
Casa Sollievo della Sofferenza IRCCS
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Conditions:
Adrenal Incidentaloma
Subclinical Hypercortisolism
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Subclinical hypercortisolism (SH) is a status of asymptomatic hypercortisolism, frequently found in patients with adrenal adenomas (estimated prevalence: 0.8-2% after 60 years of age). Although SH may...
Detailed Description
Subclinical hypercortisolism (SH) is a status of asymptomatic hypercortisolism, which is present in up to the 30% of patients with incidentally discovered adrenal adenomas (adrenal incidentalomas, AI)...
Eligibility Criteria
Inclusion
- unilateral adrenal incidentaloma larger than 1 cm
- cortisol after 1-mg overnight dexamethasone suppression test (1mgDST) between 1.8 and 5 mcg/dl
Exclusion
- hypogonadism, thyrotoxicosis, chronic renal failure and hepatic disease, alcoholism, eating, rheumatologic or hematological disorders;
- intake of drugs influencing cortisol and dexamethasone metabolism or cortisol secretion;
- signs of hypercortisolism (moon facies, striae rubrae, easy bruising);
- possible metastatic disease or radiologic features not consistent with adrenocortical adenoma at computed tomography (CT);
- pheochromocytoma and aldosteronoma;
- non-adrenal SH.
Key Trial Info
Start Date :
September 29 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 8 2022
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT04860180
Start Date
September 29 2016
End Date
December 8 2022
Last Update
April 26 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.